Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination with BYL719, a PI3K Inhibitor, in Patients with Metastatic Uveal Melanoma
A study for patients with uveal melanoma using study drug AEB071
Sponsor: Novartis Pharmaceuticals Corporation
Enrolling: Male and Female Patients
IRB Number: AAAN4901
U.S. Govt. ID: NCT02273219
Contact: Richard Carvajal MD: 212-305-2055 /
Additional Study Information: The purpose of this study is evaluate the benefits and safety of using the combination of drugs, AEB071 and BYL719 to treat patients with an advanced form of uveal melanoma. The study will have two parts. The first part twill test different dose levels of each drug.Once the highest safe dose level is found, another group of patients will be treated at that dose. Study visits will also consist of blood work, MRI's, questionnaires and ECGs.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Have you had any major surgery or extensive radiotherapy within the last month? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Richard Carvajal MD